Lisa Scherer

1.1k total citations
21 papers, 828 citations indexed

About

Lisa Scherer is a scholar working on Molecular Biology, Genetics and Virology. According to data from OpenAlex, Lisa Scherer has authored 21 papers receiving a total of 828 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 5 papers in Genetics and 4 papers in Virology. Recurrent topics in Lisa Scherer's work include RNA Interference and Gene Delivery (14 papers), Advanced biosensing and bioanalysis techniques (9 papers) and RNA and protein synthesis mechanisms (6 papers). Lisa Scherer is often cited by papers focused on RNA Interference and Gene Delivery (14 papers), Advanced biosensing and bioanalysis techniques (9 papers) and RNA and protein synthesis mechanisms (6 papers). Lisa Scherer collaborates with scholars based in United States, France and South Africa. Lisa Scherer's co-authors include John J. Rossi, Marc S. Weinberg, Haitang Li, William H. Petri, Richard C. Frank, Adrian F. Gombart, Guihua Sun, Pritsana Chomchan, Jessica Alluin and Maricela Covarrubias and has published in prestigious journals such as Nucleic Acids Research, The EMBO Journal and Nature Biotechnology.

In The Last Decade

Lisa Scherer

20 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Scherer United States 14 684 157 145 139 93 21 828
Denis Tempé France 10 647 0.9× 135 0.9× 160 1.1× 140 1.0× 102 1.1× 11 803
Grant A. Hartzog United States 18 2.0k 3.0× 170 1.1× 78 0.5× 62 0.4× 110 1.2× 28 2.1k
Naoto Inukai Japan 10 1.0k 1.5× 122 0.8× 98 0.7× 50 0.4× 111 1.2× 13 1.2k
Nina Tonnu United States 5 829 1.2× 225 1.4× 112 0.8× 87 0.6× 108 1.2× 5 954
W. Matthew Michael United States 9 1.5k 2.2× 161 1.0× 39 0.3× 97 0.7× 95 1.0× 9 1.6k
Paul D. Good United States 11 1.3k 1.9× 237 1.5× 52 0.4× 131 0.9× 55 0.6× 11 1.4k
François Bachand Canada 25 1.7k 2.5× 67 0.4× 84 0.6× 150 1.1× 76 0.8× 44 1.9k
Phaik‐Mooi Leong United States 7 354 0.5× 143 0.9× 102 0.7× 75 0.5× 82 0.9× 8 626
Ludwig Englmeier Germany 9 1.4k 2.1× 145 0.9× 115 0.8× 44 0.3× 104 1.1× 10 1.6k
Nova Fong United States 22 2.8k 4.2× 138 0.9× 64 0.4× 168 1.2× 91 1.0× 26 3.0k

Countries citing papers authored by Lisa Scherer

Since Specialization
Citations

This map shows the geographic impact of Lisa Scherer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Scherer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Scherer more than expected).

Fields of papers citing papers by Lisa Scherer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Scherer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Scherer. The network helps show where Lisa Scherer may publish in the future.

Co-authorship network of co-authors of Lisa Scherer

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Scherer. A scholar is included among the top collaborators of Lisa Scherer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Scherer. Lisa Scherer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gokulnath, Priyanka, Ane Salvador, Si‐ping Han, et al.. (2025). Development of conditional-siRNA programmable riboswitch for targeting adverse cardiac remodeling. Molecular Therapy — Nucleic Acids. 36(3). 102667–102667.
2.
Han, Si‐ping, Lisa Scherer, Ane Salvador, et al.. (2022). Programmable siRNA pro-drugs that activate RNAi activity in response to specific cellular RNA biomarkers. Molecular Therapy — Nucleic Acids. 27. 797–809. 8 indexed citations
3.
Pang, Ka Ming, Daniela Castanotto, Haitang Li, Lisa Scherer, & John J. Rossi. (2017). Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy. Nucleic Acids Research. 46(1). e6–e6. 21 indexed citations
4.
Scherer, Lisa, et al.. (2014). Optimized Lentiviral Vectors for HIV Gene Therapy: Multiplexed Expression of Small RNAs and Inclusion of MGMTP140K Drug Resistance Gene. Molecular Therapy. 22(5). 952–963. 20 indexed citations
5.
Scherer, Lisa & John J. Rossi. (2011). Ex vivo gene therapy for HIV-1 treatment. Human Molecular Genetics. 20(R1). R100–R107. 16 indexed citations
6.
Sun, Guihua, Haitang Li, Xiwei Wu, et al.. (2011). Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Research. 40(5). 2181–2196. 116 indexed citations
7.
Scherer, Lisa, Richard C. Frank, & John J. Rossi. (2007). Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Research. 35(8). 2620–2628. 35 indexed citations
8.
Scherer, Lisa, John J. Rossi, & Marc S. Weinberg. (2007). Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Therapy. 14(14). 1057–1064. 63 indexed citations
9.
Castanotto, Daniela & Lisa Scherer. (2005). Targeting Cellular Genes with PCR Cassettes Expressing Short Interfering RNAs. Methods in enzymology on CD-ROM/Methods in enzymology. 392. 173–185. 11 indexed citations
10.
Scherer, Lisa & John J. Rossi. (2004). Therapeutic Applications of RNA Interference: Recent Advances in siRNA Design. Advances in genetics. 52. 1–21. 9 indexed citations
11.
Scherer, Lisa, et al.. (2004). Rapid Assessment of Anti-HIV siRNA Efficacy Using PCR-Derived Pol III shRNA Cassettes. Molecular Therapy. 10(3). 597–603. 22 indexed citations
12.
Scherer, Lisa & John Rossi. (2004). Recent Applications of RNAi in Mammalian Systems. Current Pharmaceutical Biotechnology. 5(4). 355–360. 13 indexed citations
13.
Scherer, Lisa & John J. Rossi. (2004). RNAi Applications in Mammalian Cells. BioTechniques. 36(4). 557–561. 22 indexed citations
14.
Scherer, Lisa & John J. Rossi. (2003). Approaches for the sequence-specific knockdown of mRNA. Nature Biotechnology. 21(12). 1457–1465. 359 indexed citations
15.
Westaway, Shawn K., et al.. (2002). Enhanced Expression and HIV-1 Inhibition of Chimeric tRNALys3-Ribozymes under Dual U6 snRNA and tRNA Promoters. Molecular Therapy. 6(4). 481–489. 15 indexed citations
16.
Scherer, Lisa, et al.. (1998). Monitoring Retroviral RNA Dimerization In Vivo via Hammerhead Ribozyme Cleavage. Journal of Virology. 72(10). 8349–8353. 17 indexed citations
17.
18.
Scherer, Lisa, John D. McPherson, John J. Wasmuth, & J.Lawrence Marsh. (1992). Human dopa decarboxylase: Localization to human chromosome 7p11 and characterization of hepatic cDNAs. Genomics. 13(2). 469–471. 21 indexed citations
19.
Scherer, Lisa, et al.. (1988). Drosophila vitelline membrane genes contain a 114 base pair region of highly conserved coding sequence. Developmental Biology. 130(2). 786–788. 20 indexed citations
20.
Scherer, Lisa, et al.. (1985). Isolation and chromosomal location of putative vitelline membrane genes in Drosophila melanogaster.. The EMBO Journal. 4(1). 147–153. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026